DaVita Inc. $DVA Shares Sold by Quantbot Technologies LP

Key Points

• Quantbot Technologies LP significantly reduced its stake in DaVita Inc. by 89.3%, owning 4,671 shares worth approximately $715,000 after selling 38,989 shares.
• Various institutional investors have increased their holdings, with UMB Bank n.a. growing its stake by 65.5% during the first quarter.
• DaVita recently reported quarterly earnings of $2.95 per share, exceeding estimates, and forecasted an EPS between 10.200 and 11.300 for FY 2025.

Quantbot Technologies LP decreased its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 89.3% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,671 shares of the company's stock after selling 38,989 shares during the quarter. Quantbot Technologies LP's holdings in DaVita were worth $715,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Invesco Ltd. grew its stake in shares of DaVita by 3.4% during the first quarter. Invesco Ltd. now owns 1,642,947 shares of the company's stock valued at $251,322,000 after buying an additional 53,402 shares during the last quarter. Northern Trust Corp grew its stake in DaVita by 20.2% in the first quarter. Northern Trust Corp now owns 890,632 shares of the company's stock worth $136,240,000 after purchasing an additional 149,858 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in DaVita by 14.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 466,046 shares of the company's stock worth $69,697,000 after purchasing an additional 57,386 shares in the last quarter. Deutsche Bank AG grew its stake in DaVita by 35.2% in the fourth quarter. Deutsche Bank AG now owns 392,422 shares of the company's stock worth $58,687,000 after purchasing an additional 102,230 shares in the last quarter. Finally, Iron Triangle Partners LP bought a new position in DaVita in the fourth quarter worth approximately $38,946,000. Institutional investors own 90.12% of the company's stock.

Insider Activity at DaVita

In other news, insider James O. Hearty sold 2,351 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the sale, the insider directly owned 26,038 shares in the company, valued at $3,905,700. This trade represents a 8.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is owned by company insiders.

DaVita Stock Performance

DVA stock traded down $1.55 during midday trading on Thursday, reaching $136.01. The stock had a trading volume of 990,239 shares, compared to its average volume of 858,249. The stock has a market cap of $9.72 billion, a PE ratio of 13.37, a P/E/G ratio of 0.99 and a beta of 1.09. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.34 and a current ratio of 1.39. The firm has a fifty day simple moving average of $139.70 and a two-hundred day simple moving average of $143.37. DaVita Inc. has a 52-week low of $126.07 and a 52-week high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. The company had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.36 billion. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The firm's quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter last year, the business posted $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, equities research analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on DVA shares. Truist Financial set a $148.00 price objective on DaVita in a research note on Friday, August 8th. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research report on Friday, August 22nd. Finally, Barclays dropped their target price on DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 7th. Three analysts have rated the stock with a Hold rating, According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $164.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.